Variables
|
All patients (n=105) | NYHA I (n=11) | NYHA II (n=54) |
NYHA III-IV (n=40)
|
P-value
|
Age (years) | 61±14 | 51±10 §‡ | 62±13 | 62±14 | 0.048 |
Men, n(%) | 77 (73%) | 9 (82%) | 40 (74%) | 28 (70%) | 0.72 |
Comorbidities, n(%) | Comorbidities, n(%) | Comorbidities, n(%) | Comorbidities, n(%) | Comorbidities, n(%) | Comorbidities, n(%) |
Hypertension | 58 (55%) | 4 (36%) | 33 (61%) | 21 (53%) | 0.29 |
Diabetes mellitus | 19 (18%) | 1 (9%) | 9 (17%) | 9 (23%) | 0.55 |
Smoking, n(%) | 43 (41%) | 5 (45%) | 24 (44%) | 14 (35%) | 0.62 |
Medication, n(%) | Medication, n(%) | Medication, n(%) | Medication, n(%) | Medication, n(%) | Medication, n(%) |
ACE-I/ARBs | 97 (92%) | 9 (82%) | 52 (96%) | 36 (90%) | 0.20 |
Beta-blocker | 100 (95%) | 11(100%) | 52 (96%) | 37 (93%) | 0.67 |
MRA | 93 (89%) | 7 (64%) § | 49 (91%) | 37 (93%) | 0.02 |
Loop diuretic | 72 (69%) | 3 (27%) §‡ | 36 (67%) | 33 (83%) | 0.002 |
BNP (pg/ml) | 280 (101-665) | 156 (103-269) § | 110 (83-451) § | 620 (205-1250) | <0.001 |
§ significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant | § significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant | § significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant | § significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant | § significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant | § significant versus NYHA III-IV ‡ significant versus NYHA II Continuous data are expressed as mean ± standard deviation or median (interquartile range). Categorical data are expressed as number (percentage). n – number of patients; ACE-I – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; BNP – brain natriuretic peptide Bolded p-values are statistically significant |